Second-line (2L) treatment patterns and clinical outcomes among real-world (RW) patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with FOLFIRINOX (FFX) or gemcitabine plus nab-paclitaxel (GnP) in the first-line (1L)

被引：0
|
作者：
Paluri, Ravi Kumar
Silver, Michelle
Cockrum, Paul
Dennen, Syvart
机构：
[1] Wake Forest Univ, Winston Salem, NC USA
[2] Genesis Res Grp, Hoboken, NJ USA
[3] Ipsen Biopharmaceut Inc, Cambridge, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16322
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Real-World Cost-Effectiveness of First-Line Gemcitabine Plus Nab-Paclitaxel vs FOLFIRINOX in Patients With Advanced Pancreatic Cancer
    Arciero, Vanessa
    Luo, Jin
    Parmar, Ambica
    Dai, Wei Fang
    Beca, Jaclyn M.
    Raphael, Michael J.
    Isaranuwatchai, Wanrudee
    Habbous, Steven
    Tadrous, Mina
    Earle, Craig C.
    Biagi, Jim J.
    Mittmann, Nicole
    Arias, Jessica
    Gavura, Scott
    Chan, Kelvin K. W.
    JNCI CANCER SPECTRUM, 2022, 6 (04)
  • [32] Assessing real-world survival outcomes of patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with first-line FOLFIRINOX compared to patients from a phase 1/2 trial treated with NALIRIFOX.
    Zhu, Xuelian
    Cockrum, Paul
    Shah, Bonny
    Parzynski, Craig
    Garawin, Tamer
    Maxwell, Fiona
    Surinach, Andy
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [33] Real-world comparative effectiveness analysis of second-line (2L) nab-paclitaxel (nab-P) vs paclitaxel (Pac) in patients (Pts) with metastatic breast cancer (MBC)
    Pelletier, C.
    Parisi, M.
    Gluck, S.
    Ni, Q.
    Braiteh, F.
    ANNALS OF ONCOLOGY, 2016, 27
  • [34] Comparison of first-line (1L) treatment (tx) patterns and overall survival by age at diagnosis among patients with metastatic pancreatic ductal adenocarcinoma (mPDAC).
    Elias, Rawad
    Cockrum, Paul
    Surinach, Andy
    Wang, Shu
    Chu, Bong Chul
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [35] Efficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal adenocarcinoma: multicenter retrospective analysis
    Chae, Heejung
    Jeong, Hyehyun
    Cheon, Jaekyung
    Chon, Hong Jae
    Ryu, Hyewon
    Kim, Il-Hwan
    Kang, Myoung Joo
    Jeong, Jae Ho
    Ryoo, Baek-Yeol
    Kim, Kyu-pyo
    Yoo, Changhoon
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [36] A real-world multicenter analysis of first (1L) and second line (2L) treatment of advanced pancreatic adenocarcinoma (APC).
    Yu, Irene S.
    Spratlin, Jennifer L.
    Tang, Patricia A.
    Lee-Ying, Richard M.
    Goodwin, Rachel Anne
    Meyers, Brandon Matthew
    Ramjeesingh, Ravi
    Armstrong, Dawn Elizabeth
    Vickers, Michael M.
    Zhang, Hanbo
    Kim, Christina
    Cheung, Winson Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [37] Impact of second-line treatment (2L T) in advanced pancreatic cancer (APDAC) patients (pts) receiving first line Nab-Paclitaxel (nab-P) plus Gemcitabine (G): An Italian multicentre real life experience
    Giordano, Guido
    Febbraro, Antonio
    Milella, Michele
    Vaccaro, Vanja
    Melisi, Davide
    Foltran, Luisa
    Zagonel, Vittorina
    Zaniboni, Alberto
    Bertocchi, Paola
    Bergamo, Francesca
    Passardi, Alessandro
    Musettini, Gianna
    Giommoni, Elisa
    Iop, Aldo
    Aloi, Maria Bernardetta
    Vecchiarelli, Silvia
    Vasile, Enrico
    Lo Re, Giovanni
    Di Marco, Mariacristina
    De Vita, Ferdinando
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [38] Efficacy and safety of second-line nab-paclitaxel plus gemcitabine (nab-P plus GEM) after progression on first-line FOLFIRINOX in advanced pancreatic ductal adenocarcinoma (PDAC): Multicenter retrospective analysis
    Yoo, Changhoon
    Jeong, Hyehyun
    Chae, Heejung
    Cheon, Jaekyung
    Chon, Hong Jae
    Ryu, Hyewon
    Kim, Il-Hwan
    Jeong, Jae Ho
    Kim, Kyu-Pyo
    Ryoo, Baek-Yeol
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [39] First-line treatment patterns among patients with metastatic pancreatic ductal adenocarcinoma in the real-world setting
    Dennen, Syvart
    Harton, Joanna
    Cockrum, Paul
    Kim, George P.
    MacEwan, Joanna P.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [40] Real-world safety and medication use of second-line (2L) 5-fluorouracil (5-FU)-based regimens among patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC).
    Kim, George P.
    Cockrum, Paul
    Surinach, Andy
    Wang, Shu
    Wainberg, Zev A.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345